Eric Neuhart

ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ.

Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA.

Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. The company was founded by Robert S. Langer Jr. and Helen Marie Nugent in 2004 and is headquartered in Waltham, MA.

MedTrade Products Ltd. is a British medical device company that provides skin protectant solutions for healthcare professionals. The company, founded in 1999, is based in the UK and has subsidiaries in the UK. The company's products, available as wipes, foam pads, or foam tipped applicators, create a sacrificial layer to protect delicate skin from adhesive dressings and bodily fluids. The company's aqueous-based skin protection fluid dries to form a clear, resilient, flexible, and waterproof barrier. This breathable, invisible film offers protection from adhesive skin stripping and incontinence for up to three days between applications. MedTrade Products also specializes in wound care, trauma, and hemostasis solutions. Russell Davies Mably has been the CEO of the company since 2020.

CereHealth Corp. engages in the production of brain imaging software by utilizing high resolution gamma cameras. It specializes in Single-Photon Emission Computed Tomography (SPECT) & Positron Emission Tomography (PET). The company is headquartered in Littleton, CO.

Covington & Burling LLP provides legal services. It also provides support services in the following administrative departments including accounting, human resources, information research services, information technology services, library, operations, marketing, practice systems support, recruitment, attorney and alumni relations, and professional development. The company was founded by J. Harry Covington and Edward B. Burling on January 1, 1919 and is headquartered in Washington, DC.

Credit Suisse (UK) Ltd. (Credit Suisse-UK) is the Great Britain-based private banking subsidiary of Credit Suisse AG, itself a subsidiary of Credit Suisse Group AG (SWX: CSGN; NYSE: CS) in Switzerland. Headquartered in London, Credit Suisse-UK was founded in 1986 and provides a broad range of private banking solutions and customized financial strategies for private clients.

Citoxlab France SAS operates as a research laboratory. It offers services in toxicology, genomics, pharmacology, pharmacokinetics, bio-analysis, ecotoxicology, stability testing and regulatory affairs. The company was founded in 1969 and is headquartered in Miserey, France.

France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin.

Critical Path Institute is a nonprofit organization established in 2005 as a public and private partnership with the FDA's Critical Path Initiative program. The non-profit company is based in Tucson, AZ, and operates from Ireland with additional staff in multiple other locations. The company's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. The company orchestrates the development of drug development tools through an innovative, collaborative approach to the sharing of data and expertise, and accelerate the pace and reduce the costs of medical product development by building consensus among the participating institutions. The company was founded in 2005 by Raymond L. Woosley, Glenn C. Rice. Daniel M. Jorgensen has been the CEO of the company since 2022.

Kearny Venture Partners (Kearny Venture Partners) is a venture capital firm. The firm is headquartered in San Francisco, California.

Bouchara SAS is a French company that offers a wide range of pillows and cushions in various shapes and sizes. Bouchara is based in Paris, FR. The private company also provides storage solutions for closets, including baskets, boxes, hangers, hooks, and covers. Customers can purchase these products online and pick them up in-store.

IDB Consulting SA develops and markets information technology solutions. The company offers database management, application development, data warehousing, software support, and business intelligence services. Additionally, IDB Consulting provides outsourced accounting, budgeting, forecasting, and financial consulting services to startups and small private companies. The company partners with Oracle Corporation and IBM. Its clientele includes Everest Group, HSBC, PriceWaterHouse, Banc of America, and Meriwest Credit Union. The company was founded in 1995 and is headquartered in Paris, France

OCON Medical Ltd. engages in the research and development of intrauterine device. Its products include Intrauterine Ball IUB and IUB SCu300. The company was founded by Ilan Baram on 2008 and is headquartered in Modiin, Israel.

GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France.

Life Line Screening Holdings LLC is a private company that provides annual screenings for risks of cardiovascular disease, stroke, and other chronic diseases. The company is based in Austin, TX. The company's screenings are designed by doctors and administered by trained professionals to help detect hidden health issues before they become a serious problem. The company offers a high sensitivity c-reactive protein test (hs-crp test) to detect inflammation in the body, which can indicate the presence of atherosclerosis. The company also provides type 2 diabetes test and diagnosis services. The company was founded in 1993 and the CEO is Matt Miller.

Part of Stifel Financial Corp., Torreya Partners (Europe) LLP is a British financial advisory services company. The company is based in London, UK. The company was founded by Wilder Fulford.

Epiva Biosciences, Inc. develops immunobiotic therapeutics. The company is headquartered in Cambridge, MA.

Proterris, Inc. manufactures applications of low-dose carbon monoxide. It develops carbon monoxide for delayed graft function in renal transplant recipients and idiopathic pulmonary fibrosis. The company was founded by Jeffrey Wager and Joseph Wager and is headquartered in Boston, MA.

Placon Therapeutics, Inc. develops novel platinum therapies. The private company is based in Watertown.

Optimapharm doo engages in the data and project management services. It also offers monitoring and medical writing services. The company was founded by Gordana Greguric Cicak and Igor Cicak on May 11, 2005 and is headquartered in Zagreb, Croatia.

Travecta Therapeutics Pte Ltd. develops a novel chemistry platform for delivery of therapies to the brain. The company was founded by David L. Silver, Mahmood Ahmed, Michael Shleifer and Laurent Benissan and is headquartered in Singapore.

California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019.

Colabs International Corp. is a pharmaceutical company that develops formulations and medicines. The company’s targeted epidermal-drug delivery system which is identified as QuantaSphere Technology for cosmeceuticals, fragrances, antibacterial, anti-viral sanitizers, cleaners, and topical pharmacology. It also offers sunscreen, pest repellents, and sanitizers, soap distribution for the firm’s Klenskin products internationally. Its QuantaSphere Technology formulations provide proprietary, epidermal therapeutic effects and also blends consumer needs for a healthy lifestyle with targeted, eco-friendly, multi-tasking products. The company was founded by Laura Cohen and Lisa Leblanc on August 5, 2008 and is headquartered in Huntington Beach, CA.

ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021.

Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020.

Upperton Ltd. is a British pharmaceutical company that offers a range of services to support product development, including identification, development, monitoring, and quality control testing. Upperton is based in Nottingham, UK, and was founded in 1999 by Richard Johnson. The company has an experienced analytical team that works in conjunction with formulators to ensure the success of all projects. The company offers flexible and dynamic GMP manufacturing services for clinical supplies, from first in human through to phase III clinical supplies manufacturing. The company has extensive experience taking research projects from early proof of concept and feasibility through scale-up and onto clinical manufacture for a range of common dosage forms. The CEO is Nikki Whitfield.

Atelerix Life Sciences, Inc. is a pharmaceutical company that is developing a new drug, ATLX-0199, to address the unmet need of opioid-induced respiratory depression (OIRD) in surgical patients. The company is based in Charlottesville, VA. Atelerix Life Sciences was founded by David G. Kalergis, Benjamin Gaston, James Bates, and Stephen Lewis, with David G. Kalergis serving as the CEO since incorporation. The current drug for OIRD, Naloxone, is problematic and used infrequently because it reverses pain relief. ATLX-0199 safely stimulates opioid-depressed respiratory drive without interfering with opioid-induced analgesia.

Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.